BREAKING
NVIDIA (NVDA) eyes China AI chip re-entry as export licensing shifts to case-by-case review 3 days ago Qualcomm (QCOM) authorizes $20B stock repurchase program, raises quarterly dividend to $0.92 3 days ago UP Fintech Holding Limited Reports Strong 2025 Results 3 days ago FedEx (FDX) Q3 Earnings Crush Estimates: EPS of $5.25 Beats by 27% on $24B Revenue 3 days ago Cato Corporation 2025 Financial Results Summary 3 days ago GROY Posts Breakeven Q4 Earnings, Beating Estimates by 100% as Revenue Grows 34.2% YoY to $4.5M 3 days ago York Space Systems (YSS) Posts -$0.24 EPS vs. -$0.18 Est., Revenue Soars to $105.3M 3 days ago Scholastic (SCHL) Q3 Loss Narrows to $0.15/Share vs $0.36 Estimate, Revenue Misses at $329.1M 3 days ago Curis (CRIS) EPS Soars 210.8% to $1.23, But Revenue Plunges 67.1% to $1.1M 3 days ago Eton Pharmaceuticals (ETON) Q4 Revenue Surges 82.9% YoY to $21.3M, EPS Climbs 266.7% 3 days ago NVIDIA (NVDA) eyes China AI chip re-entry as export licensing shifts to case-by-case review 3 days ago Qualcomm (QCOM) authorizes $20B stock repurchase program, raises quarterly dividend to $0.92 3 days ago UP Fintech Holding Limited Reports Strong 2025 Results 3 days ago FedEx (FDX) Q3 Earnings Crush Estimates: EPS of $5.25 Beats by 27% on $24B Revenue 3 days ago Cato Corporation 2025 Financial Results Summary 3 days ago GROY Posts Breakeven Q4 Earnings, Beating Estimates by 100% as Revenue Grows 34.2% YoY to $4.5M 3 days ago York Space Systems (YSS) Posts -$0.24 EPS vs. -$0.18 Est., Revenue Soars to $105.3M 3 days ago Scholastic (SCHL) Q3 Loss Narrows to $0.15/Share vs $0.36 Estimate, Revenue Misses at $329.1M 3 days ago Curis (CRIS) EPS Soars 210.8% to $1.23, But Revenue Plunges 67.1% to $1.1M 3 days ago Eton Pharmaceuticals (ETON) Q4 Revenue Surges 82.9% YoY to $21.3M, EPS Climbs 266.7% 3 days ago
ADVERTISEMENT
Market News

UnitedHealth Group’s stock gains after Q1 results beat estimates

UnitedHealth Group (NYSE:UNH) beat market estimates on both revenue and earnings for the first quarter of 2019, allowing the stock to gain by 2.8% in premarket hours on Tuesday. Total revenues grew 9.3% year-over-year to $60.3 billion, driven by UnitedHealthcare Medicare & Retirement, OptumRx and OptumHealth. Net earnings attributable to UnitedHealth Group common shareholders rose […]

April 16, 2019 2 min read

UnitedHealth Group (NYSE:UNH) beat market estimates on both revenue and earnings for the first quarter of 2019, allowing the stock to gain by 2.8% in premarket hours on Tuesday. Total revenues grew 9.3% year-over-year to $60.3 billion, driven by UnitedHealthcare Medicare & Retirement, OptumRx and OptumHealth. Net earnings attributable to UnitedHealth Group common shareholders rose […]

UnitedHealth Group (NYSE:UNH) beat market estimates on both revenue and earnings for the first quarter of 2019, allowing the stock to gain by 2.8% in premarket hours on Tuesday.

Total revenues grew 9.3% year-over-year to $60.3 billion, driven by UnitedHealthcare Medicare & Retirement, OptumRx and OptumHealth.

UnitedHealth Group reports first quarter 2019 earnings

Net earnings attributable to UnitedHealth Group common shareholders rose to $3.4 billion, or $3.56 per share, from $2.8 billion, or $2.87 per share, in the year-ago period. Adjusted EPS grew 22.7% to $3.73.

Premiums totaled $47.5 billion in the quarter, up from $44 billion in the same period last year. The consolidated medical care ratio was 82%, reflecting an increase of 60 basis points year-over-year, mainly driven by the revenue effect from the deferral of the health insurance tax. Days claims payable was 49 days.

Also see: UnitedHealth Group Q1 2019 Earnings Conference Call Transcript

In the UnitedHealthcare segment, revenues grew 7.6% year-over-year to $48.9 billion, helped by revenue increases in all its divisions. Optum revenues increased 11.7% year-over-year to $26.4 billion, driven by growth across all units.

OptumHealth revenues grew 16.6% year-over-year, driven by momentum in care delivery, behavioural health, and health financial services. OptumRx revenues grew 10.6% year-over-year, reflecting increased script volumes and a higher mix of specialty drugs.

The company raised its earnings outlook for full-year 2019 and now expects GAAP EPS of $13.80 to $14.05 and adjusted EPS of $14.50 to $14.75.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

ADVERTISEMENT